Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
79.75
+0.38 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
55
56
Next >
2 Steady Stocks to Buy and Hold Forever
March 17, 2023
Investing in these companies can help you sleep easy at night.
Via
The Motley Fool
P/E Ratio Insights for AstraZeneca
March 16, 2023
Via
Benzinga
A Look Into AstraZeneca's Debt
March 15, 2023
Via
Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Via
Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
March 14, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...
Via
FinancialNewsMedia
Exposures
Product Safety
AstraZeneca's Debt Overview
March 02, 2023
Shares of AstraZeneca Inc. (NASDAQ:AZN) fell by 5.41% in the past three months. Before having a look at the importance of debt, let's look at how much debt AstraZeneca has.
Via
Benzinga
AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript
February 09, 2023
AZN earnings call for the period ending December 31, 2022.
Via
The Motley Fool
2 Top Biotech Stocks to Buy Right Now
February 09, 2023
These two companies each pay market-beating dividends to shareholders.
Via
The Motley Fool
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
March 09, 2023
Via
Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
March 09, 2023
Via
Benzinga
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Stock Jumps As Upbeat Guidance Offsets Mixed Quarterly Report
February 09, 2023
The company's guidance palliated concerns of high expenses this year, an analyst said.
Via
Investor's Business Daily
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
March 08, 2023
These companies aren't working on a vaccine, but a monoclonal antibody.
Via
Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
3 No-Brainer Stocks to Buy With $400 Right Now
March 08, 2023
A reasonably small amount of money can go a long way when it's invested in innovative businesses.
Via
The Motley Fool
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
March 06, 2023
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.
Via
InvestorPlace
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
March 06, 2023
From
AstraZeneca
Via
Business Wire
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
March 02, 2023
From
AstraZeneca
Via
Business Wire
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
March 02, 2023
Via
Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
February 28, 2023
It's not a good day for investors when their company reports a shocking plunge into the red.
Via
The Motley Fool
Why Compugen Shares Are Up Today
February 28, 2023
The company released its fourth-quarter and full-year results after the bell Monday.
Via
The Motley Fool
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
February 24, 2023
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Via
MarketBeat
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
February 16, 2023
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.
Via
Investor's Business Daily
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 16, 2023
From
AstraZeneca
Via
Business Wire
There's a Lot to Love About Mineralys' Valentine's Day IPO
February 13, 2023
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.